Fig. 5: TTK inhibitors render CAOV3 and OV90 cells more sensitive to cisplatin. | Cell Death & Disease

Fig. 5: TTK inhibitors render CAOV3 and OV90 cells more sensitive to cisplatin.

From: TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway

Fig. 5

A−C CAOV3 and OV90 cells were treated with the indicated concentrations of CDDP (0, 0.5, 1, or 2 μg/ml for CAOV3 cells and 0, 2, 4, or 8 μg/ml for OV90 cells) in combination with or without B389 (2.5 nM) for 48 h. A The MTT assay was conducted to determine cell viability. B, C The cotreatment efficiency of B389 and CDDP was assessed using the colony formation assay. D, E CAOV3 and OV90 cells were treated with DMSO, B389 (10 nM for CAOV3 and 500 nM for OV90), or CDDP (2 μg/ml for CAOV3 and 4 μg/ml for OV90) alone or in combination with B389 and CDDP. D The protein levels of cleaved PARP, cleaved caspase-3, and TTK were evaluated using western blotting. β-actin served as an endogenous control. E Apoptotic cells in different groups were detected using flow cytometry. F, G The MTT assay (F) and colony formation assay (G) were evaluated after treatment with 0, 1, 2, 4 μg/ml cisplatin and/or 10 nM CFI (data are mean ± SEM, #P > 0.05, *P < 0.05, **P < 0.01, n = 3).

Back to article page